Desquinolinyl Lenvatinib CAS 796848-79-8 Ịdị ọcha>99.0% (HPLC) Ụlọ ọrụ etiti Lenvatinib Mesylate

Nkọwa dị mkpirikpi:

1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea.

Ụdị okwu: Desquinolinyl Lenvatinib

CAS: 796848-79-8

Dị ọcha:> 99.0% (HPLC)

Ọdịdị: Gbanyụọ-Ọcha ka ntụ ntụ siri ike na-acha ọbara ọbara

Ọkara nke Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Njirimara kemịkalụ:

Aha Chemical 1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea.
Ụdị okwu Desquinolinyl Lenvatinib;Lenvatinib adịghị ọcha 16;Lenvatinib Desquinolinyl adịghị ọcha;Lenvatinib adịghị ọcha LFS-A;Lenvatinib Mesylate Intermediate Ⅲ;N- (2-Chloro-4-Hydroxyphenyl) -N'-Cyclopropyl-Urea
Nọmba CAS 796848-79-8
Nọmba CAT RF-PI1972
Ọnọdụ Ahịa N'ọkwa, Mpụta Ihe ruru Tọn
Usoro ihe omimi C10H11ClN2O2
Ibu molekụla 226.66
Ebe esi nri 364.6 ± 42.0 ℃
Njupụta 1.43±0.10 g/cm3
Ụdị Ruifu Chemical

Nkọwapụta:

Ihe Nkọwapụta
Ọdịdị Gbanyụọ-Ọcha ka ntụ ntụ siri ike na-acha ọbara ọbara
Ụzọ ịdị ọcha / nyocha > 99.0% (HPLC)
Mmiri (KF) <0.50%
Ihe fọdụrụ na mgbanye <0.20%
Otu adịghị ọcha <0.50%
Mgbakọta adịghị ọcha <1.00%
Ọla dị arọ <10ppm
Spectrum infrared Dabara na Ọdịdị
NMR Dabara na Ọdịdị
Nlele ọkọlọtọ Standardkpụrụ ụlọ ọrụ
Ojiji Ndị etiti Lenvatinib Mesylate (CAS: 857890-39-2)

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri

Uru:

1

Ajụjụ:

Ngwa:

1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea, makwaara dị ka Desquinolinyl Lenvatinib, (CAS: 796848-79-8) bụ etiti ma ọ bụ adịghị ọcha nke Lenvatinib Mesylate (CAS: 857890-39-2).Desquinolinyl Lenvatinib bụ metabolite nke Lenvatinib Mesylate bụ onye na-egbochi ọnụ nke ọtụtụ tyrosine kinases na-anabata ya gụnyere VEGF, FGF na ndị na-anabata SCF.Lenvatinib bụ ọgwụ mgbochi ọrịa kansa maka ọgwụgwọ nke ụfọdụ ụdị ọrịa kansa thyroid, yana nwekwara ike maka ọrịa cancer ndị ọzọ.Na February 13, 2015, US FDA kwadoro ọgwụ anticancer Lenvatinib maka ọgwụgwọ ọrịa cancer thyroid.Lenvatinib bụ onye na-egbochi enzyme multi-ezubere iche, na-enwe ike igbochi VEGFR2 na VEGFR3 (vaskụla endothelial growth factor receptor).Aha ahia nke Lenvatinib bụ Lenvima.

Dee ozi gị ebe a ziga anyị ya